Back to search results

AI-Powered Health Assessment for Cardiovascular, Kidney, and Metabolic Health

This study, called "Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment," is looking at new ways to help people with conditions like heart disease, kidney disease, and diabetes. It's testing two main approaches: CHAPERONE AI and CKMiq AI. CHAPERONE AI uses artificial intelligence (AI) like chatbots and copilots to help manage your health. CKMiq AI uses an algorithm based on "LIFE ESSENTIAL 8" biomarkers (health indicators from the American Heart Association) to try and reduce hospital readmissions for heart problems. The study also aims to improve your quality of life. You might be able to join if you are over 18 and have diabetes with a high A1C, heart disease with a stent or recent bypass surgery, or chronic kidney disease (stages 2-4). If you have heart failure, you would also need a recent hospitalization. The study's status is unclear, but it plans to enroll 300 people.

Study design
This is an interventional study, meaning participants will receive specific interventions. It plans to enroll 300 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The main treatment effects of CHAPERONE AI will be measured at 30, 90, and 180 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07403669

Cardiovascular Kidney and Metabolic Health Assessment and Patient Empowerment

Recruiting
NAAges 18+InterventionalTreatment
Aventyn, Inc.
~300 participants
Updated 2026-02-12 on ClinicalTrials.gov
What's tested:CHAPERONE AICKMiq AIQuality of Life

At a glance

Recruiting sites
2 of 5 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CHAPERONE AI Treatment
Measured over 30 days, 90 days and 180 days in patients CKM

Conditions

Acute MI
Heart Failure
Diabetes Mellitus
Kidney Disease

Explore related trials

Acute Myocardial InfarctionChronic Kidney DiseaseCoronary Artery DiseaseDiabetes MellitusHeart FailureHemoglobin A1C Measurement

Where it's being run

5 sites across 2 states
Arizona4
Sweden1

Study leadership

  • Kris Vijay Study Chair, MD · STUDY_CHAIR · Aventyn, Inc.
  • Zaki Lababidi PI, MD · PRINCIPAL_INVESTIGATOR · Gilbert Cardiology

Who to contact

Navin Govind Steering Committtee, MS
[email protected]
2317942328
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Men and women over 18 years of age are included
Eligible subjects must have one of the risk factor/ disease component of CKM:
Diabetes with A1C of 7.5 or higher;
or Heart disease with stent placement;
or Coronary Artery Bypass Graft (CABG) in the last 12 months;
or Chronic Kidney Disease (CKD) stage 2- 4
and, in those with Heart failure, a recent hospitalization within one week of enrollment is required

Exclusion

Those subjects who are not willing to sign an informed consent

What this trial measures

  • CHAPERONE AI Treatment30 days, 90 days and 180 days in patients CKM

    Improvement of patient outcomes will be measured by reduction of composite of Kidney failure/progression of kidney disease, Heart failure, Acute Mi events and diabetes complications and hospitalization as well as all-cause mortality through 30 days, 90 days and 180 days in patients CKM